Currently, pemigatinib and infigratinib use Foundation One as an FDA-approved companion diagnostics test (CDx) for FGFR2 fusions in intrahepatic cholangiocellular carcinoma [138]. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.